15.60
+3.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jade Biosciences
From its filings with the US Securities and Exchange Commission
Jade Biosciences is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker JBIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $127.4m. At that date it held total assets of $349.8m and shareholders' equity of $332.5m.
We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity. Our approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clinical data and that overcome shortcomings of existing product candidates in development, such as potency, bioavailability, formulation, and pharmacokinetic properties.
Our lead product candidate, JADE101, is a monoclonal antibody (“mAb”) targeting a cytokine called “A PRoliferation Inducing Ligand” (“APRIL”) that modulates plasma cell survival and immunoglobulin production, which we plan to initially develop for the treatment of IgA nephropathy (“IgAN”). Our second product candidate is JADE201, a mAb targeting B cell activating factor receptor (“BAFF-R”) for the treatment of multiple autoimmune disorders. Our third product candidate is JADE301, a mAb targeting an undisclosed pathway.
Quoted from its 10-K, filed 6 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jun 2021
- Employees
- 55
- Website
- aerovatetx.com ↗
- Head office
- 221 CRESCENT ST., WALTHAM, MA, 02453
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Habib DableIndependent Chairman of the Board$363,250
- Dr. Benjamin DakePresident, Chief Operating Officer, Secretary, since 2018$2.9m
- Mr. Timothy NoyesChief Executive Officer, Director, since 2021$3.1m
- Mr. George EldridgeChief Financial Officer, Treasurer$2.1m
- Mrs. Susan FischerExecutive Vice President - Development Operations
- Mr. Stephen YuSenior Vice President - Quality
- Dr. Marinus VerwijsChief Technical Officer$1.3m
- Dr. Ralph NivenChief Scientific Officer$433,196
- Mrs. Donna DeaHead of Regulatory Affairs
- Dr. Hunter GilliesChief Medical Officer$1.6m
- Mr. Timothy PigotChief Commercial Officer$2.5m
- Ms. Allison DorvalIndependent Director$185,795
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 65
- Social
- 45
- Governance
- 63
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Developing drugs for rare cardiopulmonary diseases with AV-101 dry powder inhaler.
- Imatinib marketed as Gleevec treats multiple cancers and improves PAH patients' six-minute walk distance.
- Focused on rare diseases with orphan drug designation for PAH treatment.
Weaknesses
- 43 full-time employees in a biotechnology sector requiring significant R&D investment.
- IPO on 30 June 2021 with limited market presence since then.
- Waltham, Massachusetts headquarters location not providing strategic advantage.
Opportunities
- Expanding AV-101 to treat other rare cardiopulmonary diseases beyond PAH.
- Growing market for orphan drugs in the Health Care sector.
- Increasing demand for treatments targeting pulmonary arterial hypertension globally.
Threats
- Competition from established biotech firms in the Health Care industry.
- Regulatory challenges for new drug approvals in the US market.
- Rising costs of clinical trials for rare disease treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.